Hemera Biosciences Raises $3.75 Million

On March 20th, Hemera Biosciences announced its Series A financing of $3.75 million.   Hemera is developing anti-complement gene based therapies for the treatment of dry and wet age related macular degeneration (AMD).  AMD is the most common cause of blindness amongst the elderly with no treatment options currently available for 90% of patients that suffer from the dry form of the disease.  Hemera has demonstrated using their proprietary recombinant molecules a very significant reduction in complement mediated damage to ocular tissues in preclinical models of dry as well as wet AMD.  The Series A financing will be used to manufacture the drug, perform animal toxicology studies and initiate a phase 1 study.  The founders and management team include Elias Reichel, MD, Jay Duker, MD, Rajendra Kumar-Singh PhD , and Adam Rogers, MD who all are on faculty at Tufts University School of Medicine.